2j5f: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
== | |||
==Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 34-jab== | |||
<StructureSection load='2j5f' size='340' side='right' caption='[[2j5f]], [[Resolution|resolution]] 3.00Å' scene=''> | <StructureSection load='2j5f' size='340' side='right' caption='[[2j5f]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
Line 6: | Line 7: | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1dnq|1dnq]], [[1dnr|1dnr]], [[1ivo|1ivo]], [[1m14|1m14]], [[1m17|1m17]], [[1mox|1mox]], [[1nql|1nql]], [[1xkk|1xkk]], [[1yy9|1yy9]], [[1z9i|1z9i]], [[2gs2|2gs2]], [[2gs7|2gs7]], [[2itn|2itn]], [[2ito|2ito]], [[2itp|2itp]], [[2itq|2itq]], [[2itt|2itt]], [[2itu|2itu]], [[2itv|2itv]], [[2itw|2itw]], [[2itx|2itx]], [[2ity|2ity]], [[2itz|2itz]], [[2j5e|2j5e]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1dnq|1dnq]], [[1dnr|1dnr]], [[1ivo|1ivo]], [[1m14|1m14]], [[1m17|1m17]], [[1mox|1mox]], [[1nql|1nql]], [[1xkk|1xkk]], [[1yy9|1yy9]], [[1z9i|1z9i]], [[2gs2|2gs2]], [[2gs7|2gs7]], [[2itn|2itn]], [[2ito|2ito]], [[2itp|2itp]], [[2itq|2itq]], [[2itt|2itt]], [[2itu|2itu]], [[2itv|2itv]], [[2itw|2itw]], [[2itx|2itx]], [[2ity|2ity]], [[2itz|2itz]], [[2j5e|2j5e]]</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2j5f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2j5f OCA], [http://pdbe.org/2j5f PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2j5f RCSB], [http://www.ebi.ac.uk/pdbsum/2j5f PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2j5f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2j5f OCA], [http://pdbe.org/2j5f PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2j5f RCSB], [http://www.ebi.ac.uk/pdbsum/2j5f PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2j5f ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 16: | Line 17: | ||
Check<jmol> | Check<jmol> | ||
<jmolCheckbox> | <jmolCheckbox> | ||
<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/j5/2j5f_consurf.spt"</scriptWhenChecked> | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/j5/2j5f_consurf.spt"</scriptWhenChecked> | ||
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | ||
<text>to colour the structure by Evolutionary Conservation</text> | <text>to colour the structure by Evolutionary Conservation</text> | ||
Line 43: | Line 44: | ||
[[Category: Yun, C H]] | [[Category: Yun, C H]] | ||
[[Category: 34-jab]] | [[Category: 34-jab]] | ||
[[Category: Alternative splicing]] | |||
[[Category: Anti-oncogene]] | [[Category: Anti-oncogene]] | ||
[[Category: Atp-binding]] | [[Category: Atp-binding]] | ||
Line 55: | Line 57: | ||
[[Category: Nucleotide-binding]] | [[Category: Nucleotide-binding]] | ||
[[Category: Phosphorylation]] | [[Category: Phosphorylation]] | ||
[[Category: Polymorphism]] | |||
[[Category: Receptor]] | [[Category: Receptor]] | ||
[[Category: Transferase]] | [[Category: Transferase]] | ||
[[Category: Transmembrane]] | [[Category: Transmembrane]] | ||
[[Category: Tyrosine-protein kinase]] | [[Category: Tyrosine-protein kinase]] | ||
[[Category: Ubl conjugation]] | |||
[[Category: Wild-type]] | [[Category: Wild-type]] |
Revision as of 10:01, 11 July 2018
Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 34-jabCrystal structure of EGFR kinase domain in complex with an irreversible inhibitor 34-jab
Structural highlights
Disease[EGFR_HUMAN] Defects in EGFR are associated with lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Function[EGFR_HUMAN] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Isoform 2 may act as an antagonist of EGF action.[14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedAs key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-molecule inhibitors. We report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue. Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src). To accommodate the new covalent bond, the quinazoline core adopts positions that are different from those seen in kinase structures with reversible quinazoline inhibitors. Based on these structures, we developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe to report the fraction of kinase necessary for cellular signaling, and we used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.,Blair JA, Rauh D, Kung C, Yun CH, Fan QW, Rode H, Zhang C, Eck MJ, Weiss WA, Shokat KM Nat Chem Biol. 2007 Apr;3(4):229-38. Epub 2007 Mar 4. PMID:17334377[27] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Human
- Receptor protein-tyrosine kinase
- Eck, M J
- Yun, C H
- 34-jab
- Alternative splicing
- Anti-oncogene
- Atp-binding
- Cell cycle
- Disease mutation
- Egfr
- Epidermal growth factor
- Glycoprotein
- Irreversible inhibitor
- Kinase
- Membrane
- Nucleotide-binding
- Phosphorylation
- Polymorphism
- Receptor
- Transferase
- Transmembrane
- Tyrosine-protein kinase
- Ubl conjugation
- Wild-type